than those with subjective symptoms at the beginning of the study ($p=0.018$). Patients with immunoglobulin E (IgE) mediated CMPA had more cutaneous symptoms (84%) than those not mediated by IgE. In 25 patients (14.9%), CMPA was IgE mediated, of whom only 24% resolved their intolerance before 1 year of age. Mean age of resolution was 18.77 ± 6.25 months.

The most commonly used substitution formulas in our study were hydrolysed lactose free milk protein formulas.

Conclusion and relevance The findings of the study showed that the presence of IgE mediated CMPA, gastrointestinal and/or cutaneous symptoms had negative effects on tolerance. No perinatal or nutritional risk factors were found to predict the persistence of CMPA.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. Carrard A, Rizzuti D, Sokollik C. Update on food allergy. *Allergy* 2015;**70**:1511–1520.

No conflict of interest.

4CPS-006 USE OF AMMONIUM TETRATHIOMOLYBDATE IN WILSON DISEASE

M Pomares Bernabeu, A Gonzalez Fernandez, M Ibañez Carrillo, AC Murcia Lopez, C Matoses Chirivella, A Navarro Ruiz*. *Hospital General Universitario De Elche, Pharmacy, Elche, Spain*

10.1136/ejhp-pharm-2020-eahpconf.107

Background and importance Wilson disease is a rare autosomal recessive disorder. It is characterised by an excessive accumulation of copper in the body, mainly in the liver, brain and cornea, leading to different manifestations, in which neuropsychiatric and hepatic manifestations predominate. Therapeutic management is based on the use of copper chelating agents (D-penicillamine, trientine) and drugs that hinder the absorption of copper (zinc salts). Ammonium tetrathiomolybdate, an experimental treatment, has also been used for periods of 8 weeks in patients with a neurological presentation under compassionate use.

Aim and objectives To evaluate the effectiveness and toxicity of ammonium tetrathiomolybdate in a patient with Wilson disease.

Material and methods A 42-year-old man was diagnosed with Wilson disease with neurological manifestations at 33 years of age, and increased transaminase levels and the presence of Kayser-Fleischer ring in both eyes. One mutation, c3359T> A (p.Leu1120*), was identified on exon 15 in the ATP7B gene. He was treated with trientine for 4 months with clinical worsening, replacing trientine with zinc sulphate and ammonium tetrathiomolybdate. At 7 weeks, the last drug was retired because of progressive worsening of liver function. Given the clinical situation, D-penicillamine was added to the basic treatment that, 6 months later, was suspended due to marked deterioration in neurological and functional conditions. Maintenance treatment with zinc sulphate was continued. In the following months, neurological symptoms progressively improved, maintaining liver function. Seven years later, due to neurological worsening, treatment was started again with ammonium tetrathiomolybdate 60 mg daily and 8 weeks later it was increased to 120 mg daily (20 mg between meals three times a day and 20 mg with each meal three times a day).

Results After 15 months of treatment with ammonium tetrathiomolybdate combined with zinc sulphate, the patient

experienced improvements in motor and cognitive-behavioural symptoms, and maintained normal haematological and hepatic function. Before starting treatment with ammonium tetrathiomolybdate, at the analytical level, we found: copper in urine 56 µg/24 hours, ceruloplasmin 2 mg/dL and copper in blood 34 µg/dL; after 8 weeks (with a dose of 60 mg/day) the values were 111 µg/24 hours, 2 mg/dL and 63 µg/dL, respectively, and currently the values are 44 µg/24 hours, 2 mg/dL and 16 µg/dL.

Conclusion and relevance In our patient, ammonium tetrathiomolybdate was effective and well tolerated for a prolonged period. It could be an alternative in patients with neurological manifestations.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-007 PHARMACEUTICAL CARE AS A MEANS OF PREVENTION AGAINST DRUG IATROGENESIS: CASE OF ORAL ANTICOAGULANTS

D Andre*, C Chatain, MC Chaumais, A Rieutord, S Roy. *Antoine Béclère, 92140 Clamart, Clamart, France*

10.1136/ejhp-pharm-2020-eahpconf.108

Background and importance Oral anticoagulants (OAC) have a significant risk of adverse events, particularly in the transition of care where OAC are initiated, modified or transitionally interrupted. Pharmaceutical care through medication reconciliation and patient counselling could improve the benefit to risk ratio of these drugs.

Aim and objectives To use OAC therapy as prioritisation criteria for performing pharmaceutical care: medication reconciliation and pharmaceutical counselling.

Material and methods A prospective and interventional single centre study was conducted from March to September 2018 in the medicine and surgical units. Patients with an OAC prescribed from the outpatient sector were included. These patients received medication reconciliation at admission and discharge as well as patient specific pharmaceutical counselling about OAC to provide education. Their knowledge was assessed with a multiple choice questionnaire.

Frequency and type of reconciliation discrepancies were studied at admission and discharge. The gravity rating of this discrepancies was measured using the Cornish *et al* scale, with three levels of severity: low, moderate and high.

At patient discharge, a summary of the knowledge acquired by the patient about OAC and medication reconciliation was provided to them.

Results A total of 162 patients were included in the study. Medication reconciliation at admission allowed the detection of 133 unintentional discrepancies (0.8/patient) of which 16 represented a high risk to the patient, including 9 errors about OAC prescribing. Concerning medication reconciliation at discharge, 51 unintentional discrepancies (0.3/patient) were detected: 12 represented a high risk to the patient, including 8 errors about OAC prescribing.

The acceptance rate of the discrepancies was 86% in total and reflected the degree of severity of the pharmaceutical interventions. This result reached 96% if we took into account discrepancies with a real clinical impact. Concerning the pharmaceutical multiple choice questionnaire, the success rate was 66%.